Sangamo Therapeutics Inc (NASDAQ:SGMO)’s stock price shot up 6.4% during trading on Tuesday . The stock traded as high as $11.60 and last traded at $11.37, 3,097,950 shares changed hands during trading. An increase of 75% from the average session volume of 1,770,560 shares. The stock had previously closed at $10.69.
A number of equities research analysts have weighed in on the stock. Zacks Investment Research lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 16th. Wedbush reiterated a “hold” rating and set a $11.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, November 12th. HC Wainwright assumed coverage on shares of Sangamo Therapeutics in a report on Monday, August 26th. They set a “buy” rating and a $16.00 price target on the stock. Finally, BidaskClub raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 28th. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $13.50.
The company has a market cap of $1.36 billion, a price-to-earnings ratio of -16.86 and a beta of 2.84. The firm has a 50 day moving average price of $9.55 and a two-hundred day moving average price of $10.24. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.10.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.10. Sangamo Therapeutics had a negative return on equity of 30.33% and a negative net margin of 159.12%. The company had revenue of $21.96 million for the quarter, compared to analyst estimates of $12.16 million. During the same period in the previous year, the firm earned ($0.13) earnings per share. The firm’s quarterly revenue was down 6.8% on a year-over-year basis. On average, equities analysts expect that Sangamo Therapeutics Inc will post -1.21 earnings per share for the current year.
A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its stake in shares of Sangamo Therapeutics by 13.2% in the 2nd quarter. BlackRock Inc. now owns 9,432,178 shares of the biopharmaceutical company’s stock valued at $101,584,000 after purchasing an additional 1,098,030 shares during the last quarter. Nuveen Asset Management LLC acquired a new position in Sangamo Therapeutics in the second quarter valued at $8,516,000. Vanguard Group Inc. lifted its holdings in Sangamo Therapeutics by 7.7% in the second quarter. Vanguard Group Inc. now owns 8,309,161 shares of the biopharmaceutical company’s stock valued at $89,490,000 after buying an additional 596,573 shares during the period. Candriam Luxembourg S.C.A. bought a new stake in Sangamo Therapeutics during the second quarter valued at $4,450,000. Finally, Macquarie Group Ltd. boosted its position in Sangamo Therapeutics by 247.8% during the second quarter. Macquarie Group Ltd. now owns 400,000 shares of the biopharmaceutical company’s stock valued at $4,308,000 after acquiring an additional 285,000 shares during the last quarter. Hedge funds and other institutional investors own 70.78% of the company’s stock.
About Sangamo Therapeutics (NASDAQ:SGMO)
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Recommended Story: How does quantitative easing work?
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.